6月19日，清华大学神经工程实验室神经美学研究团队独家回应科技日报，对网友关注的"神秘高科 技组织"进行揭秘。 近日，小红书上出现了一篇题为"在清华不懂就问，这是个什么神秘高科技组织？"的图文笔记，引 发1.6万点赞，两千多条留言。 小红书截图 图上，8位头戴"神奇发帽"的人坐在新清华学堂舞剧演出《咏春》的观众席上，网友纷纷留言，有 人以为是集体染发看演出的行为艺术，有人说这像是被蕨类植物寄生，还有人担心会不会对身体有影 响？ 高小榕教授在首届"艺术·心理·脑科学"暨神经美学大会上发言 真实剧场神经美学实验 "这是国内首次将无创脑机接口技术系统性应用于美学与艺术研究，也是国内首个真实剧场神经美 学实验。我们的实验目标是在现场真实剧院场景下，结合神经科学研究方法，借助高精度脑电设备同步 捕捉观众在欣赏演出时的神经活动，对观众的审美体验进行解码。我们希望通过这一跨学科的探索，推 动技术在理解人类审美体验中的新应用，为艺术认知研究开辟新的路径。"清华大学生物医学工程学院 神经工程实验室主任高小榕教授告诉科技日报记者。 神经美学是神经科学的分支学科，是艺术人文与自然科学交叉融合的新兴学科。其核心是探讨人类 如何在神经 ...

撰文丨王聪 编辑丨王多鱼 排版丨水成文 血管类器官 （Vascular Organoid，VO） 已成为心血管研究领域的重要模型，通过人多能干细胞 （hPSC） 定向分化为内皮细胞、血管壁细胞等，可以构建出具有可灌注功能的三维血管网络。此类模型不仅能够模拟内皮细胞与血管壁细胞之间的动态相互作用，还可复 现器官特异的血管微环境。 血管类器官在模拟血管发育、血管疾病、药物筛选和再生医学等多个方向均展现出巨大的潜力。然而，当前的分化方案还存在诸多问题，包括分化异 质性大、所需时间长、基质胶和生长因子依赖、成本高昂、血管细胞不成熟，以及体内成血管能力低等，这些问题限制了血管类器官在血管研究以及临床转化的 潜力。 2025 年 6 月 1 3 日，北京大学基础医学院 /血管稳态与重构全国重点实验室/细胞稳态与衰老性重大疾病北京研究中心 王凯 课题组与美国哈佛医学院/波士顿儿 童医院 Juan Melero-Martin 团队合作 （ 博士后 公丽岩 为第一作者） 在 Cell Stem Cell 期刊发表了题为： Rapid generation of functional vascular organoids via ...

撰文丨王聪 编辑丨王多鱼 排版丨水成文 本周，华人学者作为通讯作者或第一作者，在国际顶尖学术期刊 Cell 上发表了 4 篇研究论文。这些研究包括 线粒体对多能性的影响、 完整组织的 多模态遗传筛选平台、抗衰老间充质祖细胞疗法、补体蛋白攻击的开关。 强制线粒体 自噬，揭示线粒体对哺乳动物多能性的影响 2025 年 6 月 10 日，德克萨斯大学西南医学中心 吴军 教授团队在国际顶尖学术期刊 Cell 上发表了题 为： Unraveling mitochondrial influence on mammalian pluripotency via enforced mitophagy 的研究论文 【1】 。 该研究 开发了一种 强制线粒体 自噬 新技术，能够在体外或体内减少或完全去除线粒体，使用该技术，研究团队揭示了线粒体对细胞多能性的影响 ，还发现了线粒体数量的降低会导致着床前小鼠胚胎发育延迟。这项研究为探索线粒体在发育、疾病和跨物种生物学中的作用开辟了新途径，还有望 促进线粒体疾病的研究和疗法开发。 Perturb-Multi： 哺乳动物完整组织的多模态遗传筛选平台 2025 年 6 月 12 日， 哈佛大 ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Whil ...

Core Viewpoint - Kodiak Sciences Inc. has seen a 10.5% increase in share price over the past month, outperforming the S&P 500, but estimates have trended downward, indicating potential challenges ahead [1][2]. Group 1: Earnings and Estimates - The consensus estimate for Kodiak Sciences has shifted downward by 10.35% over the past month [2]. - The stock has a Zacks Rank of 3 (Hold), suggesting an expectation of in-line returns in the coming months [4]. Group 2: VGM Scores - Kodiak Sciences has a subpar Growth Score of D and a Momentum Score of F, with an overall aggregate VGM Score of F, placing it in the lowest quintile for investment strategies [3]. Group 3: Industry Performance - Kodiak Sciences is part of the Zacks Medical - Biomedical and Genetics industry, where Apellis Pharmaceuticals has gained 17.7% over the past month [5]. - Apellis Pharmaceuticals reported revenues of $166.8 million, reflecting a year-over-year decline of 3.2%, and is expected to post a loss of $0.44 per share for the current quarter, indicating a 57.1% change from the previous year [6].

Core Viewpoint - Fate Therapeutics has seen a significant increase in share price, gaining approximately 61.5% over the past month, outperforming the S&P 500, raising questions about the sustainability of this trend leading up to the next earnings report [1] Group 1: Earnings and Estimates - The consensus estimate for Fate Therapeutics has shifted upward by 12.68% in the past month, indicating positive revisions [2] - The stock has a Zacks Rank of 2 (Buy), suggesting expectations for above-average returns in the coming months [4] Group 2: VGM Scores - Fate Therapeutics has a subpar Growth Score of D, a Momentum Score of D, and a Value Score of D, placing it in the bottom 40% for investment strategies, resulting in an overall VGM Score of F [3] Group 3: Industry Performance - Fate Therapeutics is part of the Zacks Medical - Biomedical and Genetics industry, where Novavax has reported a revenue of $666.66 million, reflecting a year-over-year increase of 610.3% [5] - Novavax is expected to report a loss of $0.12 per share for the current quarter, with a year-over-year change of -112.1%, and has a Zacks Rank of 3 (Hold) [6]

Company Overview - Exelixis shares have decreased by approximately 7.2% over the past month, underperforming the S&P 500 [1] - The most recent earnings report is crucial for understanding the key drivers affecting the stock [1] Earnings Estimates - Estimates for Exelixis have trended upward in the past month, with the consensus estimate shifting by 15.91% [2] VGM Scores - Exelixis has a strong Growth Score of A and a momentum score of A, with a value score of B, placing it in the top 40% for this investment strategy [3] - The aggregate VGM Score for Exelixis is A, indicating strong overall performance across multiple investment strategies [3] Outlook - The upward trend in estimates suggests a promising outlook for Exelixis, which holds a Zacks Rank 2 (Buy) [4] - An above-average return is expected from the stock in the upcoming months [4] Industry Performance - Exelixis is part of the Zacks Medical - Biomedical and Genetics industry, where Puma Biotech has gained 22.1% over the past month [5] - Puma Biotech reported revenues of $46 million for the last quarter, reflecting a year-over-year increase of 5% [5] - Puma Biotech's expected earnings for the current quarter are $0.11 per share, indicating a significant change of 320% from the previous year [6] - Puma Biotech also holds a Zacks Rank 2 (Buy) and has a VGM Score of A [6]

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.While many investors like to look for moment ...

A month has gone by since the last earnings report for Xenon Pharmaceuticals (XENE) . Shares have added about 8.7% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Xenon Pharmaceuticals due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.How Have Estimates Been Moving Sin ...

证券代码：688089 证券简称：嘉必优 公告编号：2025-047 嘉必优生物技术（武汉）股份有限公司 第四届监事会第六次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 嘉必优生物技术（武汉）股份有限公司（以下简称"公司"）第四届监事 会第六次会议（以下简称"本次会议"）于 2025 年 6 月 9 日以现场结合通讯形 式召开。会议通知已于 2025 年 6 月 5 日通过邮件等方式送达全体监事。本次会 议应出席监事 3 人，实际出席监事 3 人，会议由监事会主席王纪召集并主持。 本次会议的召集、召开和表决程序符合有关法律法规、规范性文件和《公司章 程》的规定。 二、监事会会议审议情况 经与会监事审议表决，通过了以下议案： （一）审议通过了《关于调整公司发行股份及支付现金购买资产并募集配 套资金暨关联交易方案且本次方案调整不构成重大调整的议案》 股份及支付现金购买资产并募集配套资金暨关联交易方案的议案》等议案，公 司拟通过发行股份及支付现金的方式购买上海欧易生物医学科技有限公司 原交 ...